top of page

The CEO of Corbus on nectin-4 ADCs, integrin biology, and an alternative to GLPs for weight loss

  • May 14, 2024
  • 1 min read

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition for cancer, and describes the oral weight loss pill Corbus will be advancing to the clinic.





Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page